Literature DB >> 18617060

A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia.

Kazuhiko Kakihana1, Fumito Kubo, Shihoko Wakabayashi, Tetsuya Kurosu, Tohru Miki, Naomi Murakami, Osamu Miura.   

Abstract

MLL located at 11q23 is fused with a variety of partner genes by recurrent chromosomal translocations in acute leukemias. ELL, the MLL partner gene located on chromosome 19p13.1, encodes an RNA polymerase II transcriptional elongation factor, which also possesses the N-terminal region involved in the inhibition of transcription initiation. Here we report a case of chronic myelomonocytic leukemia (CMML) with a 46,XY,t(11;19)(q23;p13.1) karyotype that transformed to acute myeloid leukemia (AML) without showing any karyotypic evolution. Interphase fluorescent in situ hybridization analysis showed the split MLL signals in 95% of bone marrow cells when the diagnosis of CMML was made and the percentage of blasts was 1.2%. Sequence analysis of reverse-transcriptional polymerase chain reaction product revealed a novel variant form of MLL-ELL transcript in which MLL exon 10 was fused to ELL exon 3. MLL has been fused to ELL exon 2 in all the previously reported MLL-ELL transcripts, which have always been associated with AML. It is deduced that the variant form of MLL-ELL may be defective not only in inhibition of transcription initiation, but also in transcriptional elongation. Thus, a possibility is raised that the unique clinical presentation of the present case with t(11;19)(q23;p13.1) might be related to the variant form of MLL-ELL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617060     DOI: 10.1016/j.cancergencyto.2008.04.001

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia.

Authors:  Suguru Uemura; Akihiro Tamura; Atsuro Saito; Daiichiro Hasegawa; Nanako Nino; Takehito Yokoi; Teppei Tahara; Aiko Kozaki; Kenji Kishimoto; Toshiaki Ishida; Keiichiro Kawasaki; Takeshi Mori; Noriyuki Nishimura; Minenori Ishimae; Mariko Eguchi; Yoshiyuki Kosaka
Journal:  Int J Hematol       Date:  2017-07-01       Impact factor: 2.490

2.  Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.

Authors:  Tomoya Muto; Masahiro Takeuchi; Atsuko Yamazaki; Yasumasa Sugita; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Nobuyuki Aotsuka; Tohru Iseki; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2015-03-11       Impact factor: 2.490

Review 3.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

4.  MLL-ELL fusion gene in an acute myelomonocytic leukemia patient transformed from acute promyelocytic leukemia.

Authors:  Wang Qiang Hu; Xiao Xia Wang; Rong Rong Yang; Kang Yu
Journal:  Clin Case Rep       Date:  2015-04-09

5.  Rare MLL-ELL fusion transcripts in childhood acute myeloid leukemia-association with young age and myeloid sarcomas?

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Gitte Kerndrup; Signe Spetalen; Anne Tierens; Liv T N Osnes; Kristin Andersen; Lil-Sofie Ording Müller; Marit Hellebostad; Bernward Zeller; Sverre Heim
Journal:  Exp Hematol Oncol       Date:  2016-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.